FLAGSTAFF, Ariz., April 3, 2019 /PRNewswire/ -- SenesTech, Inc.
(NASDAQ: SNES), a developer of proprietary technologies for
managing animal pest populations through fertility control, is
excited to announce that Ed Albe has
joined SenesTech as Senior Vice President of Commercialization.
"In our earnings call last Thursday, we discussed our commercial
accomplishments cast in the structure of our new commercial
verticals of Structural/Cities, Food Production, Storage, and
Animal Facilities. We introduced this strategy as a prelude to
our addition of Ed Albe to our
team," commented Dr. Loretta Mayer,
CEO and co-founder of SenesTech. "Ed officially joined our team
last January. In the past 90 days we have worked together to
provide Ed with insight into our company with an emersion strategy
of detailed company history and performance, criss-crossing the US
from New York to California meeting our major customers and
hearing their 'voice,' culminating with a Board-approved
commercialization strategy for 2019 and beyond. It is with
confidence and excitement that we hand the reins of
commercialization (Marketing, Sales, Manufacturing and
Distribution) to Ed for a bountiful future."
Ed is a high technology industry veteran with an impressive
track record of bringing innovative, often esoteric, products to
market. He has provided the commercialization and go-to-market
strategy for startups, as well as nascent companies introducing
novel products to the pharmaceutical, biotechnology, specialty
chemical, and photonics marketplaces. He is especially adept at
turning around underperforming marketing and sales assets to
accelerate the time to profitable revenue. Ed received his MBA from
Denver's Regis University and is generally regarded within
high technology as a lean startup expert.
"I'm delighted that Dr. Mayer and Dr. Dyer, the co-founders of
SenesTech, asked me to join their team! SenesTech, and it's
flagship product ContraPest®, are poised to dramatically enhance
next generation integrated pest management (IPM) protocols. I am
especially pleased to join a company that has created a fertility
control product for rats which does not have the deleterious impact
on our ecology as rodenticides. SenesTech's innovative culture and
raison d'être had me instantly," commented Ed Albe.
Drs. Cheryl Dyer and Loretta Mayer, co-founders, responded, "Welcome
aboard, Ed."
About SenesTech
SenesTech is changing the paradigm of pest management by
targeting the root cause of the problem: reproduction.
ContraPest® is an innovative technology with an
approach that targets the reproductive capabilities of both sexes
in rat populations, inducing egg loss in female rats and impairing
sperm development in males. Using a proprietary bait delivery
method, ContraPest® is dispensed in a highly palatable
liquid formulation that promotes sustained consumption by rat
communities. ContraPest® is designed, formulated and
dispensed to be low hazard for handlers and non-target species such
as wildlife, livestock and pets, where the active ingredients break
down rapidly.
We believe ContraPest® will establish a new paradigm
in rodent control, resulting in a decreased reliance on lethal
options. For more information visit the SenesTech website at
www.senestech.com.
Safe Harbor Statement
This release contains
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans,
results, or strategies and are generally preceded by words such as
"may," "future," "plan" or "planned," "will" or "should,"
"expected," "anticipates," "draft," "eventually" or "projected."
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors and other risks
identified in our filings with the Securities and Exchange
Commission. Forward looking statements include, but are not limited
to, our expectation regarding sales commitments, our expectation
regarding the conversion of sales commitments and programs to
revenue, our belief that our product is more humane, less harmful
to the environment and more effective than traditional methods, and
our belief that ContraPest will establish a new paradigm in rodent
control without environmental effects of rodenticides. All
forward-looking statements contained in this press release speak
only as of the date on which they were made and are based on
management's assumptions and estimates as of such date. We do not
undertake any obligation to publicly update any forward-looking
statements, whether as a result of the receipt of new information,
the occurrence of future events or otherwise.
CONTACT:
Investor: Robert Blum,
Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700,
senestech@lythampartners.com
Company: Tom Chesterman, Chief
Financial Officer, SenesTech, Inc., 928-779-4143
View original content to download
multimedia:http://www.prnewswire.com/news-releases/senestech-announces-commercial-acceleration-with-new-senior-vice-president-edward-albe-300823779.html
SOURCE SenesTech, Inc.